NSE: MARKSANS | BSE: 524404

Mid-range Performer

Download real time

168.15 0.11 (0.07%)

New 52W Low in past week

587.8K NSE+BSE Volume

NSE 02 Apr, 2026 3:31 PM (IST)

7,619.9

Market Cap

Above industry Median

Beta 1Year

Very High Volatility

US FDA Approval

Marksans Pharma gets US FDA nod for Benzonatate capsules, with a market size of $1.8 bn in 2025 See details

Marksans Pharma Ltd. share price target and research reports

Name: Latest research reports of Marksans Pharma Ltd. authored by Ventura and published by - Trendlyne research reports.
Item: Marksans Pharma Ltd.
Rating: 5
Author: Ventura

Latest analyst research reports with target prices and PDF download for MARKSANS, BSE:524404 Marksans Pharma Ltd.

Search Inside the pdf :

Marksans Pharma Ltd.

14 Mar 2024

168.15

0.07%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Target

Ventura

Growth in demand and capabilities

Institutional Investors have decreased holdings from 22.20% to 14.04% in Dec 2025 qtr

Marksans Pharma Ltd.

04 Oct 2023, 12:00AM

168.15

0.07%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Target

Ventura

Consolidating on the back of the Teva acquisition

Number of FII/FPI investors decreased from 146 to 137 in Dec 2025 qtr

Marksans Pharma Ltd.

22 Jul 2023

168.15

0.07%

Strong growth in OTC business to drive profitability

Buy: Marksans Pharma Ltd.

StoxBox - BP Wealth

Marksans Pharma has entered into a Business Transfer Agreement with Tevapharm to acquire its business relating to the manufacture and supply of bulk pharmaceutical formulations in Goa. The company plans to manufacture tablets, hard and soft gel capsules, ointments, gummies, and creams from the new capacity.

Institutional Investors have decreased holdings from 22.20% to 14.04% in Dec 2025 qtr

Marksans Pharma Ltd.

21 Oct 2022

168.15

0.07%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Ventura

Growth visibility with reasonable valuation

Marksans Pharma has lost -27.88% in the last 1 Year

Marksans Pharma Ltd.

06 Jun 2022

168.15

0.07%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Target

Arihant Capital

FII/FPI have decreased holdings from 16.92% to 8.13% in Dec 2025 qtr

Marksans Pharma Ltd.

14 Oct 2021

168.15

0.07%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Arihant Capital

We had hosted Investor Conference on 29th & 30th September 2021 where 15 companies participated at our Arihant Rising Star's Virtual Summit. Key takeaways from the conference are as follows:...

Institutional Investors have decreased holdings from 22.20% to 14.04% in Dec 2025 qtr

Marksans Pharma Ltd.

11 Jun 2018

168.15

0.07%

Marksans Pharma

Hold: Marksans Pharma Ltd.

Recommendation Target

Centrum Broking

Source: Bloomberg, Centrum Research, *as on 8th June 2018 Recommendation and key risks: We have revised our FY19E and FY20E EPS downwards by 41% and 43% respectively. We downgrade MPL to Hold from Buy rating, with a TP of Rs31 based on 18x March'20E EPS of Rs1.7, and a 10.2%% upside from CMP. Key positive upsides would be additional ANDA approvals from US FDA...

Number of FII/FPI investors decreased from 146 to 137 in Dec 2025 qtr

Marksans Pharma Ltd.

11 Jun 2018

168.15

0.07%

Marksans Pharma

Hold: Marksans Pharma Ltd.

Recommendation Target

Centrum Broking

FII/FPI have decreased holdings from 16.92% to 8.13% in Dec 2025 qtr

Marksans Pharma Ltd.

19 Feb 2018

168.15

0.07%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Recommendation Target

Centrum Broking

Recommendation and key risks: We have revised our FY18E and FY19E EPS downwards by 3% and 19% respectively. We upgrade MPL to Buy from Hold rating, with a TP of Rs55 based on 18x March'20E EPS of Rs3.0, and a 45.3% upside from CMP. Key positive upsides would be additional ANDA approvals from US FDA and...

Number of FII/FPI investors decreased from 146 to 137 in Dec 2025 qtr

Is Marksans Pharma Ltd. worth buying?

1442 Votes:

Buy 80.72%

Sell 10.06%

Hold 9.22%